Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

Diabetes drug could treat illicit drug addiction

Diabetes drug could treat illicit drug addiction

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Extended release exenatide outperforms twice daily regimen

Extended release exenatide outperforms twice daily regimen

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb completes acquisition of Amylin

Scientists identify mechanisms by which GLP-1 protects against kidney disease, diabetes

Scientists identify mechanisms by which GLP-1 protects against kidney disease, diabetes

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb to acquire Amylin

Exenatide ‑ a better alternative for add-on therapy?

Exenatide ‑ a better alternative for add-on therapy?

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Exendin-4 drug effectively suppresses craving for food

Exendin-4 drug effectively suppresses craving for food

European Commission grants marketing authorization for use of BYETTA with basal insulin

European Commission grants marketing authorization for use of BYETTA with basal insulin

Amylin prices public offering of 13,000,000 shares of common stock

Amylin prices public offering of 13,000,000 shares of common stock

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Oramed files provisional patent application with USPTO for combination diabetes therapy

Oramed files provisional patent application with USPTO for combination diabetes therapy

Amylin outlines key strategic priorities for 2012

Amylin outlines key strategic priorities for 2012

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin and Lilly terminate exenatide alliance, resolve litigation

Exenatide's rapid anti-inflammatory effect may inhibit atherosclerosis

Exenatide's rapid anti-inflammatory effect may inhibit atherosclerosis

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Two newer Type 2 diabetes drugs could be linked to increased risk of pancreatic cancer

Two newer Type 2 diabetes drugs could be linked to increased risk of pancreatic cancer